MucoidPseudomonas aeruginosa is a marker of poor su

Pediatric Pulmonology

12, 158-161

DOI: 10.1002/ppul.1950120306

Citation Report

#	Article	IF	Citations
1	Nosocomially Acquired Pseudomonas cepacia Infection in Patients with Cystic Fibrosis. Infection Control and Hospital Epidemiology, 1993, 14, 124-126.	1.0	8
2	NosocomiallyAcquiredPseudomonas cepaciaInfection in Patients with Cystic Fibrosis. Infection Control and Hospital Epidemiology, 1993, 14, 124-126.	1.0	15
3	Possible Nosocomial Transmission of Pseudomonas cepacia in Patients With Cystic Fibrosis. JAMA Pediatrics, 1994, 148, 805.	3.6	34
4	Mechanism of Action of Antibiotics in Chronic Pulmonary Pseudomonas Infection. Advances in Pharmacology, 1994, 30, 53-84.	1.2	5
5	Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. Journal of Clinical Epidemiology, 1995, 48, 1041-1049.	2.4	263
6	Cystic fibrosis.. American Journal of Respiratory and Critical Care Medicine, 1996, 154, 1229-1256.	2.5	859
7	The prognosis of cystic fibrosis in the Western Cape region of South Africa. Journal of Paediatrics and Child Health, 1996, 32, 323-326.	0.4	7
8	Potential of preventing Pseudomonas aeruginosa lung infections in cystic fibrosis patients: Experimental studies in animals. Apmis, 1996, 104, 5-42.	0.9	18
9	A prognostic model for the prediction of survival in cystic fibrosis. Thorax, 1997, 52, 313-317.	2.7	72
10	Pseudomonas aeruginosa: Assessment of Risk from Drinking Water. Critical Reviews in Microbiology, 1997, 23, 47-75.	2.7	177
12	Long term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax, 1998, 53, 732-737.	2.7	70
13	Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study Â Commentary: Management in paediatric and adult cystic fibrosis centres improves clinical outcome. BMJ: British Medical Journal, 1998, 316, 1771-1775.	2.4	209
14	Î±₁-Antitrypsin deficiency alleles and the <I>Taq</I>-I G â†' A allele in cystic fibrosis lung disease. European Respiratory Journal, 1998, 11, 873-879.	3.1	54
15	Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease. Clinical and Experimental Immunology, 1999, 117, 561-567.	1.1	53
16	Antipseudomonal antibiotics and cystic fibrosis. Australian and New Zealand Journal of Medicine, 1999, 29, 5-8.	0.5	1
17	Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?. Australian and New Zealand Journal of Medicine, 1999, 29, 15-21.	0.5	18
18	Changing Epidemiology ofPseudomonas aeruginosa Infection in Danish Cystic Fibrosis Patients (1974-1995). , 1999, 28, 159-166.		161
19	Management of Patients with Cystic Fibrosis. Disease Management and Health Outcomes, 1999, 6, 93-108.	0.3	11

#	Article	IF	Citations
20	Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respiratory Medicine, 1999, 93, 476-480.	1.3	142
21	Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist1*Address for correspondence: Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115, USA. Microbes and Infection, 2000, 2, 1051-1060.	1.0	1,191
22	Secondary genetic factors in cystic fibrosis lung disease. Thorax, 2000, 55, 446-446.	2.7	9
23	Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Pediatrics, 2001, 138, 699-704.	0.9	390
25	Inpatient Care of the Adult With an Exacerbation of Cystic Fibrosis. AACN Advanced Critical Care, 2001, 12, 293-304.	1.9	3
26	The Role of Nebulized Antibiotics in Treating Serious Respiratory Infections. Journal of Chemotherapy, 2001, 13, 354-362.	0.7	29
27	Administration of Aerosolized Antibiotics in Cystic Fibrosis Patients. Chest, 2001, 120, 107S-113S.	0.4	84
28	Paediatric origins of adult lung disease bullet 7: Cystic fibrosis. Thorax, 2001, 56, 237-241.	2.7	58
29	Chinks in the Armor of the Airway. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 11-13.	1.4	8
30	Synergistic Activities of Macrolide Antibiotics against Pseudomonas aeruginosa , Burkholderia cepacia , Stenotrophomonas maltophilia , and Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2002, 46, 1105-1107.	1.4	103
31	Long-term Benefits of Inhaled Tobramycin in Adolescent Patients With Cystic Fibrosis. Chest, 2002, 121, 55-63.	0.4	158
32	A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. European Respiratory Journal, 2002, 20, 658-664.	3.1	251
33	Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax, 2002, 57, 142-145.	2.7	91
34	Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. Current Opinion in Pulmonary Medicine, 2002, 8, 521-528.	1.2	28
35	Persistent and aggressive bacteria in the lungs of cystic fibrosis children. British Medical Bulletin, 2002, 61, 81-96.	2.7	72
36	TOBIÂ®: reducing the impact of pseudomonal infection. British Journal of Hospital Medicine, 2002, 63, 421-425.	0.3	10
37	The Rationale for Aerosolized Antibiotics. Pharmacotherapy, 2002, 22, 71S-79S.	1.2	34
38	Complete genome sequence and comparative analysis of the metabolically versatile Pseudomonas putida KT2440. Environmental Microbiology, 2002, 4, 799-808.	1.8	1,218

#	Article	IF	Citations
39	Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatric Pulmonology, 2002, 34, 91-100.	1.0	910
40	The Role of Inflammation in the Pathophysiology of CF Lung Disease. Clinical Reviews in Allergy and Immunology, 2002, 23, 005-028.	2.9	214
41	Genome mosaicism is conserved but not unique inPseudomonas aeruginosaisolates from the airways of young children with cystic fibrosis. Environmental Microbiology, 2003, 5, 1341-1349.	1.8	102
42	Infection Control Recommendations for Patients With Cystic Fibrosis: Microbiology, Important Pathogens, and Infection Control Practices to Prevent Patient-to-Patient Transmission. Infection Control and Hospital Epidemiology, 2003, 24, S6-S52.	1.0	198
43	Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Journal of Cystic Fibrosis, 2003, 2, 29-34.	0.3	573
44	Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. American Journal of Infection Control, 2003, 31, S6-S62.	1.1	131
45	Inflammatory markers in cystic fibrosis patients with transmissiblePseudomonas aeruginosa. European Respiratory Journal, 2003, 22, 503-506.	3.1	46
46	Non-Genetic Influences on Cystic Fibrosis Lung Disease: The Role of Sociodemographic Characteristics, Environmental Exposures, and Healthcare Interventions. Seminars in Respiratory and Critical Care Medicine, 2003, 24, 639-652.	0.8	49
47	New medical management techniques for acute exacerbations of chronic rhinosinusitis. Current Opinion in Otolaryngology and Head and Neck Surgery, 2003, 11, 27-32.	0.8	14
48	The cystic fibrosis transmembrane conductance regulator. , 2003, , 117-138.		1
49	Current and future treatment of cystic fibrosis. , 2003, , 428-450.		0
50	Cystic fibrosis at a Brazilian center of excellence: clinical and laboratory characteristics of 104 patients and their association with genotype and disease severity. Jornal De Pediatria, 2004, 80, 371-379.	0.9	38
51	Gender-Specific Pulmonary Disease. , 2004, , 25-35.		0
52	Azithromycin for Improving Pulmonary Function in Cystic Fibrosis. Annals of Pharmacotherapy, 2004, 38, 1520-1524.	0.9	10
53	Infection Control in Cystic Fibrosis. Clinical Microbiology Reviews, 2004, 17, 57-71.	5.7	271
54	Type III Secretion Phenotypes of Pseudomonas aeruginosa Strains Change during Infection of Individuals with Cystic Fibrosis. Journal of Clinical Microbiology, 2004, 42, 5229-5237.	1.8	177
55	Pseudomonas aeruginosa Biofilms Exposed to Imipenem Exhibit Changes in Global Gene Expression and Î²-Lactamase and Alginate Production. Antimicrobial Agents and Chemotherapy, 2004, 48, 1175-1187.	1.4	302
56	Reduction in prevalence of chronicPseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatric Pulmonology, 2004, 37, 104-110.	1.0	74

#	Article	IF	Citations
57	CF: An X-ray database to assess effect of aerosolized tobramycin. Pediatric Pulmonology, 2004, 38, 23-30.	1.0	19
58	â€œMaintaining the Horizontal Lineâ€: early intervention and prevention of CF lung disease. Journal of Cystic Fibrosis, 2004, 3, 63-66.	0.3	14
59	Inhaled Tobramycin. Chest, 2005, 127, 1098-1101.	0.4	8
60	Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clinical Microbiology and Infection, 2005, 11, 690-703.	2.8	134
61	Tratamiento antimicrobiano frente a la colonizaciÃ³n pulmonar por Pseudomonas aeruginosa en el paciente con fibrosis quÃstica. Archivos De Bronconeumologia, 2005, 41, 1-25.	0.4	55
62	Monitoring microaerobic denitrification of Pseudomonas aeruginosa by online NAD(P)H fluorescence. Journal of Industrial Microbiology and Biotechnology, 2005, 32, 622-628.	1.4	18
63	Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of Aerosolized Interferon Gamma-1b in Patients With Mild to Moderate Cystic Fibrosis Lung Disease. Pediatric Pulmonology, 2005, 39, 209-218.	1.0	55
64	Prophylactic Antibiotics in Cystic Fibrosis: A Conviction without Evidence?. Pediatric Pulmonology, 2005, 40, 471-476.	1.0	35
65	Pseudomonas aeruginosa: Clinical Research. , 2005, 34, 131-137.		1
66	Eradication therapy for earlyPseudomonas aeruginosainfection in CF: many questions still unanswered. European Respiratory Journal, 2005, 26, 373-375.	3.1	17
67	Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre. European Respiratory Journal, 2005, 25, 474-481.	3.1	37
68	Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2005, 49, 5013-5017.	1.4	46
69	Effects of Segregation on an EpidemicPseudomonas aeruginosaStrain in a Cystic Fibrosis Clinic. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1020-1025.	2.5	77
70	Longitudinal Development of Mucoid <EMPH>Pseudomonas aeruginosa</EMPH> Infection and Lung Disease Progression in Children With Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2005, 293, 581.	3.8	471
71	Inhaled Tobramycin in Nonâ€”Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection with Pseudomonas Aeruginosa. Annals of Pharmacotherapy, 2005, 39, 39-44.	0.9	201
72	Pseudomonas aeruginosa in public swimming pools and bathroom water of patients with cystic fibrosis. Journal of Cystic Fibrosis, 2005, 4, 227-231.	0.3	47
73	Multidrugâ€“resistant organisms in cystic fibrosis: management and infectionâ€“control issues. Expert Review of Anti-Infective Therapy, 2006, 4, 807-819.	2.0	45
74	Azithromycin reduces spontaneous and induced inflammation in Î”F508 cystic fibrosis mice. Respiratory Research, 2006, 7, 134.	1.4	88

#	Article	IF	Citations
75	Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2006, 5, 261-263.	0.3	24
76	Diagnosing and managing infection in CF. Paediatric Respiratory Reviews, 2006, 7, S151-S153.	1.2	26
77	Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatric Pulmonology, 2006, 41, 656-665.	1.0	105
78	Premature cellular senescence induced by pyocyanin, a redox-active Pseudomonas aeruginosa toxin. Free Radical Biology and Medicine, 2006, 41, 1670-1677.	1.3	73
79	Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis. Thorax, 2006, 61, 684-688.	2.7	41
80	A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18131-18136.	3.3	213
81	Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2006, 57, 306-311.	1.3	715
82	Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis. Proceedings of the American Thoracic Society, 2007, 4, 370-377.	3.5	57
83	Cystic Fibrosis: A Review of Epidemiology and Pathobiology. Clinics in Chest Medicine, 2007, 28, 279-288.	0.8	150
84	Approaches to the Treatment of Initial Pseudomonas aeruginosa Infection in Children Who Have Cystic Fibrosis. Clinics in Chest Medicine, 2007, 28, 307-318.	0.8	8
85	Infection Control Practice in Cystic Fibrosis Centers. Clinics in Chest Medicine, 2007, 28, 381-404.	0.8	6
86	Novel conjugate vaccine for the prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients. Drug Development Research, 2007, 68, 512-521.	1.4	0
87	Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatric Pulmonology, 2007, 42, 256-262.	1.0	61
88	Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety. Pediatric Pulmonology, 2007, 42, 307-313.	1.0	173
89	Predictors of mortality in adults with cystic fibrosis. Pediatric Pulmonology, 2007, 42, 525-532.	1.0	135
90	Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatric Pulmonology, 2007, 42, 751-756.	1.0	60
91	Early intervention in CF: How to monitor the effect. Pediatric Pulmonology, 2007, 42, 1002-1007.	1.0	9
92	Les manifestations respiratoires de la mucoviscidose. Revue Francophone Des Laboratoires, 2007, 2007, 37-42.	0.0	0

#	Article	IF	Citations
93	Treatment of children with cystic fibrosis: central, local or both?. Acta Paediatrica, International Journal of Paediatrics, 2002, 91, 972-977.	0.7	8
94	A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatric Pulmonology, 2008, 43, 47-58.	1.0	96
95	Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure. Pediatric Pulmonology, 2008, 43, 511-513.	1.0	13
96	Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients. Pediatric Pulmonology, 2008, 43, 463-471.	1.0	58
97	Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatric Pulmonology, 2008, 43, 874-881.	1.0	56
98	A laminar flow model of aerosol survival of epidemic and non-epidemic strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis. BMC Microbiology, 2008, 8, 105.	1.3	24
99	Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. Trends in Molecular Medicine, 2008, 14, 120-133.	3.5	104
100	Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. , 2008, , CD006961.		8
101	Virulence determinants from a cystic fibrosis isolate of Pseudomonas aeruginosa include isocitrate lyase. Microbiology (United Kingdom), 2008, 154, 1616-1627.	0.7	70
102	Respiratory Manifestations. , 2008, , 871-887.		1
103	ClpXP proteases positively regulate alginate overexpression and mucoid conversion in Pseudomonas aeruginosa. Microbiology (United Kingdom), 2008, 154, 2119-2130.	0.7	90
104	Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 921-928.	2.5	337
105	Long-Term Benefits of Inhaled Tobramycin in Children with Cystic Fibrosis: First Clinical Observations from Poland. Respiration, 2008, 75, 178-181.	1.2	8
106	Cystic Fibrosis Lung Disease in Adult Patients. Postgraduate Medicine, 2008, 120, 64-74.	0.9	7
109	Eradication of early Pseudomonas infection in cystic fibrosis. Chronic Respiratory Disease, 2009, 6, 99-107.	1.0	29
110	Augmented effect of early antibiotic treatment in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2009, 64, 1241-1250.	1.3	21
111	Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis. Thorax, 2009, 64, 535-540.	2.7	169
112	Impact of Pseudomonas and Staphylococcus Infection on Inflammation and Clinical Status in Young Children with Cystic Fibrosis. Journal of Pediatrics, 2009, 154, 183-188.e3.	0.9	205

#	Article	IF	Citations
113	Comparison of the sensitivity of culture, PCR and quantitative real-time PCR for the detection of Pseudomonas aeruginosain sputum of cystic fibrosis patients. BMC Microbiology, 2009, 9, 244.	1.3	56
114	Mucoid Inquilinus limosus in a young adult with cystic fibrosis. Pediatric Pulmonology, 2009, 44, 619-621.	1.0	12
115	IL1B polymorphisms modulate cystic fibrosis lung disease. Pediatric Pulmonology, 2009, 44, 580-593.	1.0	49
116	Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF population. Pediatric Pulmonology, 2009, 44, 594-601.	1.0	40
117	Cystic fibrosis HRCT scores correlate strongly with pseudomonas infection. Pediatric Pulmonology, 2009, 44, 1107-1117.	1.0	27
118	Longâ€term pulmonary outcome after meconium ileus in cystic fibrosis. Pediatric Pulmonology, 2009, 44, 1201-1206.	1.0	19
119	Clinical Immunology Review Series: An approach to the management of pulmonary disease in primary antibody deficiency. Clinical and Experimental Immunology, 2009, 155, 147-155.	1.1	49
120	Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism. Journal of Cystic Fibrosis, 2009, 8, 43-46.	0.3	15
121	Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden. Journal of Cystic Fibrosis, 2009, 8, 135-142.	0.3	32
122	Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa. Journal of Cystic Fibrosis, 2009, 8, 400-404.	0.3	12
123	The Role of Pseudomonas Lipopolysaccharide in Cystic Fibrosis Airway Infection. Sub-Cellular Biochemistry, 2010, 53, 241-253.	1.0	54
124	ATP7B detoxifies silver in ciliated airway epithelial cells. Toxicology and Applied Pharmacology, 2010, 243, 315-322.	1.3	22
125	Baseline Characteristics and Factors Associated With Nutritional and Pulmonary Status at Enrollment in the Cystic Fibrosis EPIC Observational Cohort. Pediatric Pulmonology, 2010, 45, 934-944.	1.0	51
126	Factors associated with mucoid transition of Pseudomonas aeruginosa in cystic fibrosis patients. Clinical Microbiology and Infection, 2010, 16, 617-623.	2.8	8
127	Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. Environmental Microbiology, 2010, 12, 1293-1303.	1.8	203
128	Gender Differences in Pediatric Pulmonary Disease. , 2010, , 35-50.		0
129	Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis. Infection and Drug Resistance, 2010, 3, 123.	1.1	6
130	The Changing Microbial Epidemiology in Cystic Fibrosis. Clinical Microbiology Reviews, 2010, 23, 299-323.	5.7	697

#	Article	IF	Citations
131	The Role of Mucoidy in Virulence of Bacteria from theBurkholderia cepaciaComplex: A Systematic Proteomic and Transcriptomic Analysis. Journal of Infectious Diseases, 2010, 202, 770-781.	1.9	43
132	Cystic fibrosis and survival to 40 years: a case-control study. European Respiratory Journal, 2010, 36, 1277-1283.	3.1	43
133	Defining routes of airborne transmission ofPseudomonas aeruginosain people with cystic fibrosis. Expert Review of Respiratory Medicine, 2010, 4, 519-529.	1.0	37
134	Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy. Journal of Cystic Fibrosis, 2010, 9, 1-16.	0.3	93
135	An aerobiological model of aerosol survival of different strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis. Journal of Cystic Fibrosis, 2010, 9, 64-68.	0.3	21
136	Genotype based evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis patients. Journal of Cystic Fibrosis, 2010, 9, 99-103.	0.3	24
137	Estrogen aggravates inflammation in Pseudomonas aeruginosa pneumonia in cystic fibrosis mice. Respiratory Research, 2010, 11, 166.	1.4	83
138	Contribution of oxygen-limiting conditions to persistent infection of Pseudomonas aeruginosa. Future Microbiology, 2010, 5, 603-621.	1.0	58
139	Evaluation of the efficacy of real-time polymerase chain reaction for the routine early detection of Pseudomonas aeruginosa in cystic fibrosis sputum and throat swab specimens. Diagnostic Microbiology and Infectious Disease, 2010, 68, 358-365.	0.8	13
140	Pseudomonas aeruginosa in cystic fibrosis patients with CFTR I1234V in a large kindred family. Journal of Cystic Fibrosis, 2010, 9, S120.	0.3	1
142	Lack of correlation between pulmonary disease and cystic fibrosis transmembrane conductance regulator dysfunction in cystic fibrosis: a case report. Journal of Medical Case Reports, 2010, 4, 117.	0.4	1
143	Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. Expert Opinion on Pharmacotherapy, 2010, 11, 1373-1385.	0.9	17
144	Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis. Clinical Microbiology Reviews, 2011, 24, 29-70.	5.7	341
145	Pseudomonas Skin Infection. American Journal of Clinical Dermatology, 2011, 12, 157-169.	3.3	111
146	Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. Journal of Cystic Fibrosis, 2011, 10, 54-61.	0.3	284
147	New and investigational treatments in cystic fibrosis. Therapeutic Advances in Respiratory Disease, 2011, 5, 275-282.	1.0	10
149	Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics. Respiratory Medicine, 2011, 105, S2-S8.	1.3	26
150	Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. Journal of Cystic Fibrosis, 2011, 10, S75-S78.	0.3	123

#	Article	IF	Citations
151	Tobramycin administered by the TOBI® Podhaler® for persons with cystic fibrosis: a review. Medical Devices: Evidence and Research, 2011, 4, 179.	0.4	50
153	Evolution and Adaptation in Pseudomonas aeruginosa Biofilms Driven by Mismatch Repair System-Deficient Mutators. PLoS ONE, 2011, 6, e27842.	1.1	53
154	Treatment of cystic fibrosis following infant screening. Therapy: Open Access in Clinical Medicine, 2011, 8, 613-622.	0.2	3
155	Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation. Transplant Infectious Disease, 2011, 13, 616-621.	0.7	6
156	Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatric Pulmonology, 2011, 46, 230-238.	1.0	144
157	Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study. BMJ: British Medical Journal, 2011, 343, d4662-d4662.	2.4	79
158	Tobramycin Inhalation Powderâ„¢: a novel drug delivery system for treating chronicPseudomonas aeruginosainfection in cystic fibrosis. Expert Review of Respiratory Medicine, 2011, 5, 609-622.	1.0	30
159	Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). Journal of Antimicrobial Chemotherapy, 2011, 66, 2398-2404.	1.3	37
160	Comparative Efficacy and Safety of 4 Randomized Regimens to Treat EarlyPseudomonas aeruginosaInfection in Children With Cystic Fibrosis. JAMA Pediatrics, 2011, 165, 847.	3.6	199
161	Eradication ofPseudomonas aeruginosain an adult patient with cystic fibrosis. American Journal of Health-System Pharmacy, 2011, 68, 319-322.	0.5	3
162	Inhaled Aztreonam Lysine for Cystic Fibrosis. Journal of Pharmacy Technology, 2012, 28, 75-81.	0.5	0
163	Genetic relatedness of Pseudomonas aeruginosa isolates among a paediatric cystic fibrosis patient cohort in Ireland. Journal of Medical Microbiology, 2012, 61, 64-70.	0.7	15
164	Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis. Current Pharmaceutical Design, 2012, 18, 726-736.	0.9	47
165	New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas. Current Pharmaceutical Design, 2012, 18, 696-725.	0.9	45
166	Future Directions in Early Cystic Fibrosis Lung Disease Research. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 887-892.	2.5	68
167	Health-related quality of life in Cystic Fibrosis patients infected with transmissible Pseudomonas aeruginosa strains: cohort study. JRSM Short Reports, 2012, 3, 1-7.	0.6	13
168	New Therapies in Cystic Fibrosis. Current Pharmaceutical Design, 2012, 18, 614-627.	0.9	21
169	Update in Cystic Fibrosis 2011. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 933-936.	2.5	9

#	Article	IF	Citations
170	Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Current Medical Research and Opinion, 2012, 28, 1059-1067.	0.9	12
171	Transmissible strains ofPseudomonas aeruginosain cystic fibrosis lung infections. European Respiratory Journal, 2012, 40, 227-238.	3.1	141
172	Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic. Journal of Cystic Fibrosis, 2012, 11, 49-52.	0.3	27
173	Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)â€"A cause for concern?. Journal of Cystic Fibrosis, 2012, 11, 173-179.	0.3	45
174	Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. , 2012, 11, CD009528.		20
175	AnaerobicPseudomonas aeruginosaand other obligately anaerobic bacterial biofilms growing in the thick airway mucus of chronically infected cystic fibrosis patients: an emerging paradigm or â€œOld Hatâ€?. Expert Opinion on Therapeutic Targets, 2012, 16, 859-873.	1.5	26
176	Mucoid Pseudomonas aeruginosa caused by mucA mutations result in activation of TLR2 in addition to TLR5 in airway epithelial cells. Biochemical and Biophysical Research Communications, 2012, 428, 150-154.	1.0	17
177	Detection of Pseudomonas aeruginosa in sputum headspace through volatile organic compound analysis. Respiratory Research, 2012, 13, 87.	1.4	42
178	Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatric Pulmonology, 2012, 47, 44-52.	1.0	91
179	Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonology, 2012, 47, 125-134.	1.0	78
180	Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatric Pulmonology, 2012, 47, 135-143.	1.0	99
181	Analysis of the associations between lung function and clinical features in preschool children with Cystic Fibrosis. Pediatric Pulmonology, 2012, 47, 574-581.	1.0	32
182	Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis. Pediatric Pulmonology, 2012, 47, 1113-1122.	1.0	12
183	Mapping global effects of the anti-sigma factor MucA in Pseudomonas fluorescens SBW25 through genome-scale metabolic modeling. BMC Systems Biology, 2013, 7, 19.	3.0	32
184	Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study. Clinical Drug Investigation, 2013, 33, 419-427.	1.1	72
185	Inhaled aztreonam lysine: an evidence-based review. Expert Opinion on Pharmacotherapy, 2013, 14, 2115-2124.	0.9	13
186	Truncation of type IV pilin induces mucoidy in P seudomonas aeruginosa strain PAO579. MicrobiologyOpen, 2013, 2, 459-470.	1.2	12
187	Synthase-dependent exopolysaccharide secretion in Gram-negative bacteria. Trends in Microbiology, 2013, 21, 63-72.	3.5	206

#	Article	IF	Citations
188	Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. Journal of Cystic Fibrosis, 2013, 12, 482-486.	0.3	117
189	T-Cell Immunotherapy in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 564-566.	2.5	8
190	Early lung disease in cystic fibrosis. Lancet Respiratory Medicine,the, 2013, 1, 148-157.	5.2	80
191	Considerations for Targeting Î²-Catenin Signaling in Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 566-568.	2.5	26
192	Halting the spread of epidemic Pseudomonas aeruginosa in an adult cystic fibrosis centre: a prospective cohort study. JRSM Short Reports, 2013, 4, 1-8.	0.6	40
193	Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatric Pulmonology, 2013, 48, 943-953.	1.0	31
194	Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment. Jornal Brasileiro De Pneumologia, 2013, 39, 495-512.	0.4	49
195	The Pseudomonas aeruginosa AlgZR two-component system coordinates multiple phenotypes. Frontiers in Cellular and Infection Microbiology, 2014, 4, 82.	1.8	57
196	Genetic relatedness and host specificity of Pseudomonas aeruginosa isolates from cystic fibrosis and non-cystic fibrosis patients. Infection and Drug Resistance, 2014, 7, 309.	1.1	5
197	Is There a Role for Antimicrobial Stewardship in Cystic Fibrosis?. Annals of the American Thoracic Society, 2014, 11, 1116-1119.	1.5	16
198	Twenty-Five-Year Outbreak of Pseudomonas aeruginosa Infecting Individuals with Cystic Fibrosis: Identification of the Prairie Epidemic Strain. Journal of Clinical Microbiology, 2014, 52, 1127-1135.	1.8	49
199	Editorial Commentary: How Can Understanding the Phenotype of Pseudomonas aeruginosa Lead to More Successful Eradication Strategies in Cystic Fibrosis?. Clinical Infectious Diseases, 2014, 59, 632-634.	2.9	0
200	Inhaled liposomal amikacin. Expert Review of Respiratory Medicine, 2014, 8, 401-409.	1.0	41
201	Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study. Drug Design, Development and Therapy, 2014, 8, 209.	2.0	69
202	Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. Clinical Microbiology and Infection, 2014, 20, O983-O990.	2.8	58
203	Evaluation of the Pharmacokinetics and Pharmacodynamics of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infections Using Data from Two Phase 2 Clinical Studies. Antimicrobial Agents and Chemotherapy, 2014, 58, 5005-5015.	1.4	24
204	The Burden of Disease and the Need for a Simple Staging System in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 765-767.	2.5	4
205	Genotypic diversity of Pseudomonas aeruginosa in cystic fibrosis siblings in Qatar using AFLP fingerprinting. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 265-271.	1.3	12

#	Article	IF	Citations
206	Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 172-178.	0.3	31
207	Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment. Journal of Cystic Fibrosis, 2014, 13, 534-541.	0.3	10
208	Early detection of infection with Pseudomonas aeruginosa in cystic fibrosis: The Holy Grail or an achievable goal?. Journal of Cystic Fibrosis, 2014, 13, 491-493.	0.3	4
209	Emerging drugs for cystic fibrosis. Expert Opinion on Emerging Drugs, 2014, 19, 143-155.	1.0	23
210	Anti-PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology, 2014, 49, 650-658.	1.0	90
211	The cystic fibrosis gender gap: Potential roles of estrogen. Pediatric Pulmonology, 2014, 49, 309-317.	1.0	49
212	Influences of nasal lavage collection-, processing- and storage methods on inflammatory markers â€" Evaluation of a method for non-invasive sampling of epithelial lining fluid in cystic fibrosis and other respiratory diseases. Journal of Immunological Methods, 2014, 404, 41-51.	0.6	41
213	Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 542-549.	0.3	15
214	Cystic Fibrosis Transmembrane Conductance Regulator andPseudomonas. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 763-765.	2.5	3
215	Pseudomonas aeruginosa In Vitro Phenotypes Distinguish Cystic Fibrosis Infection Stages and Outcomes. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 289-297.	2.5	113
216	Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-7.	1.3	12
217	Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. , 2015, , CD009528.		13
218	Plasmid carriage can limit bacteriaâ€"phage coevolution. Biology Letters, 2015, 11, 20150361.	1.0	17
219	Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis. BMC Pulmonary Medicine, 2015, 15, 161.	0.8	10
220	Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. , 2015, , CD006961.		6
221	A cross-sectional study of growth, nutritional status and body proportions in children and adolescents at a medical center specializing in the treatment of cystic fibrosis in Poland. Archives of Medical Science, 2015, 1, 155-163.	0.4	13
222	Pseudomonas aeruginosaAcquisition in Cystic Fibrosis Patients in Context of Otorhinolaryngological Surgery or Dentist Attendance: Case Series and Discussion of Preventive Concepts. Case Reports in Infectious Diseases, 2015, 2015, 1-9.	0.2	12
223	Genome Sequence of Mucoid Pseudomonas aeruginosa Strain FRD1. Genome Announcements, 2015, 3, .	0.8	4

#	Article	IF	Citations
224	ColobreatheÂ® for the Treatment of Cystic Fibrosis-Associated Pulmonary Infections. Pulmonary Therapy, 2015, 1, 19-30.	1.1	13
225	Use of Inhaled Tobramycin in Cystic Fibrosis. Advances in Therapy, 2015, 32, 1-9.	1.3	21
226	Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor. Clinical Infectious Diseases, 2015, 60, 703-712.	2.9	198
227	Is infection with hypermutable Pseudomonas aeruginosa clinically significant?. Journal of Cystic Fibrosis, 2015, 14, 347-352.	0.3	8
228	Cystic fibrosis microbiology: Advances in antimicrobial therapy. Journal of Cystic Fibrosis, 2015, 14, 551-560.	0.3	83
229	Proteaseâ€“antiprotease imbalances differ between Cystic Fibrosis patients' upper and lower airway secretions. Journal of Cystic Fibrosis, 2015, 14, 324-333.	0.3	17
230	Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response. BMC Infectious Diseases, 2015, 15, 145.	1.3	46
231	Proximity to blue spaces and risk of infection with Pseudomonas aeruginosa in cystic fibrosis: A caseâ€“control analysis. Journal of Cystic Fibrosis, 2015, 14, 741-747.	0.3	18
232	Clinical applications of pulmonary delivery of antibiotics. Advanced Drug Delivery Reviews, 2015, 85, 1-6.	6.6	46
233	Impact of alginate-producing Pseudomonas aeruginosa on alveolar macrophage apoptotic cell clearance. Journal of Cystic Fibrosis, 2015, 14, 70-77.	0.3	31
234	Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. Pediatric Pulmonology, 2015, 50, 42-48.	1.0	59
235	The hierarchy quorum sensing network in Pseudomonas aeruginosa. Protein and Cell, 2015, 6, 26-41.	4.8	930
236	Inhaled antimicrobial therapy â€“ Barriers to effective treatment. Advanced Drug Delivery Reviews, 2015, 85, 24-43.	6.6	99
237	Azithromycin Attenuates Pseudomonas-Induced Lung Inflammation by Targeting Bacterial Proteins Secreted in the Cultured Medium. Frontiers in Immunology, 2016, 7, 499.	2.2	10
238	Modular Approach to Select Bacteriophages Targeting Pseudomonas aeruginosa for Their Application to Children Suffering With Cystic Fibrosis. Frontiers in Microbiology, 2016, 7, 1631.	1.5	27
239	Ambroxol inhibits mucoid conversion of Pseudomonas aeruginosa and contributes to the bactericidal activity of ciprofloxacin against mucoid P. aeruginosa biofilms. Apmis, 2016, 124, 611-618.	0.9	7
240	Continuous alternating inhaled antibiotic therapy in CF: A single center retrospective analysis. Journal of Cystic Fibrosis, 2016, 15, 802-808.	0.3	16
241	Assessing the Airway Microbiota in Cystic Fibrosis. Clinical Microbiology Newsletter, 2016, 38, 179-184.	0.4	2

#	Article	IF	Citations
242	Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time. BMC Pulmonary Medicine, 2016, 16, 176.	0.8	37
243	Chelation of Membrane-Bound Cations by Extracellular DNA Activates the Type VI Secretion System in Pseudomonas aeruginosa. Infection and Immunity, 2016, 84, 2355-2361.	1.0	29
244	Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 67-74.	1.3	33
245	Clinical Isolates of Pseudomonas aeruginosa from Chronically Infected Cystic Fibrosis Patients Fail To Activate the Inflammasome during Both Stable Infection and Pulmonary Exacerbation. Journal of Immunology, 2016, 196, 3097-3108.	0.4	28
247	A cross-sectional analysis of daytime versus nocturnal polysomnographic respiratory parameters in cystic fibrosis during early adolescence. Journal of Cystic Fibrosis, 2017, 16, 250-257.	0.3	13
248	Effect of aerosolized antipseudomonals on <scp>P</scp>seudomonas positivity and bronchiolitis obliterans syndrome after lung transplantation. Transplant Infectious Disease, 2017, 19, e12688.	0.7	13
249	Partial Restoration of CFTR Function in cftr-Null Mice following Targeted Cell Replacement Therapy. Molecular Therapy, 2017, 25, 654-665.	3.7	18
250	Microbiology of the Upper and Lower Airways in Pediatric Cystic Fibrosis Patients. Otolaryngology - Head and Neck Surgery, 2017, 157, 302-308.	1.1	13
251	Pseudomonas aeruginosa and post-tracheotomy bacterial respiratory tract infection readmissions. Pediatric Pulmonology, 2017, 52, 1212-1218.	1.0	28
252	Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. The Cochrane Library, 2017, 6, CD006961.	1.5	15
253	Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	22
254	Long-term clinical outcomes of â€˜Prairie Epidemic Strainâ€™Pseudomonas aeruginosainfection in adults with cystic fibrosis. Thorax, 2017, 72, 333-339.	2.7	17
256	Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis. BMC Infectious Diseases, 2017, 17, 411.	1.3	16
257	Corticosteroid-resistant inflammatory signalling in Pseudomonas-infected bronchial cells. ERJ Open Research, 2017, 3, 00144-2016.	1.1	3
258	Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. The Cochrane Library, 2017, 10, CD009528.	1.5	34
259	The Cystic Fibrosis Airway Microbiome and Pathogens. , 2017, , .		1
260	Establishing the diagnosis of chronic colonization with Pseudomonas aeruginosa of cystic fibrosis patients: Comparison of the European consensus criteria with genotyping of P. aeruginosa isolates. Journal of Cystic Fibrosis, 2018, 17, 729-735.	0.3	12
261	Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 428-439.	1.4	237

#	Article	IF	Citations
262	Pseudomonas aeruginosa and Bronchiectasis. , 2018, , 157-180.		1
264	KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis, 2018, 17, 484-491.	0.3	63
265	Sputum Active Polymyxin Lipopeptides: Activity against Cystic FibrosisPseudomonas aeruginosaIsolates and Their Interactions with Sputum Biomolecules. ACS Infectious Diseases, 2018, 4, 646-655.	1.8	19
266	Defining chronic Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 292-293.	0.3	5
267	Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study. Clinical Infectious Diseases, 2018, 67, 1089-1095.	2.9	47
268	Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 341-347.	0.3	38
269	Pseudomonas aeruginosa Regulated Intramembrane Proteolysis: Protease MucP Can Overcome Mutations in the AlgO Periplasmic Protease To Restore Alginate Production in Nonmucoid Revertants. Journal of Bacteriology, 2018, 200, .	1.0	13
270	Tracheostomy in children: Epidemiology and clinical outcomes. Pediatric Pulmonology, 2018, 53, 1269-1275.	1.0	32
271	Gender differences in bronchiectasis: a real issue?. Breathe, 2018, 14, 108-121.	0.6	50
272	Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clinical Microbiology Reviews, 2019, 32, .	5.7	264
273	Filamentous bacteriophages are associated with chronic Pseudomonas lung infections and antibiotic resistance in cystic fibrosis. Science Translational Medicine, 2019, 11, .	5.8	80
274	Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung. Journal of Cystic Fibrosis, 2019, 18, 796-803.	0.3	36
275	Aztreonam Lysine Inhalation Solution in Cystic Fibrosis. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2019, 13, 117954841984282.	0.5	10
277	Serum-Associated Antibiotic Tolerance in Pediatric Clinical Isolates of Pseudomonas aeruginosa. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 671-679.	0.6	6
278	Material properties of interfacial films of mucoid and nonmucoid Pseudomonas aeruginosa isolates. Acta Biomaterialia, 2020, 118, 129-140.	4.1	3
279	Novel quinazolinone inhibitors of the Pseudomonas aeruginosa quorum sensing transcriptional regulator PqsR. European Journal of Medicinal Chemistry, 2020, 208, 112778.	2.6	32
280	Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases. Journal of Clinical Medicine, 2020, 9, 3800.	1.0	63
281	The human respiratory tract microbial community structures in healthy and cystic fibrosis infants. Npj Biofilms and Microbiomes, 2020, 6, 61.	2.9	18

#	Article	IF	Citations
282	Local and Systemic Alterations of the L-Arginine/Nitric Oxide Pathway in Sputum, Blood, and Urine of Pediatric Cystic Fibrosis Patients and Effects of Antibiotic Treatment. Journal of Clinical Medicine, 2020, 9, 3802.	1.0	7
283	Cystic Fibrosis Patients Infected With Epidemic Pseudomonas aeruginosa Strains Have Unique Microbial Communities. Frontiers in Cellular and Infection Microbiology, 2020, 10, 173.	1.8	8
284	Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. The Cochrane Library, 2021, 2021, CD006961.	1.5	1
285	Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. The Cochrane Library, 2020, 6, CD009528.	1.5	6
286	The role of inflammation in cystic fibrosis pulmonary exacerbations. Expert Review of Respiratory Medicine, 2020, 14, 889-903.	1.0	3
287	Lung function determinants and mortality of children and adolescents with cystic fibrosis in South Africa 2007â€2016. Pediatric Pulmonology, 2020, 55, 1381-1387.	1.0	5
288	Scnn1b -Transgenic BALB/c Mice as a Model of Pseudomonas aeruginosa Infections of the Cystic Fibrosis Lung. Infection and Immunity, 2020, 88, .	1.0	6
289	Scope and limitations on aerosol drug delivery for the treatment of infectious respiratory diseases. Journal of Controlled Release, 2020, 325, 276-292.	4.8	41
290	Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for Pseudomonas aeruginosa survival. Scientific Reports, 2020, 10, 10935.	1.6	25
291	Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 8-16.	0.3	25
292	Early acquisition and conversion of Pseudomonas aeruginosa in Hispanic youth with cystic fibrosis in the United States. Journal of Cystic Fibrosis, 2021, 20, 424-431.	0.3	9
293	Killing three birds with one BPI: Bactericidal, opsonic, and anti-inflammatory functions. Journal of Translational Autoimmunity, 2021, 4, 100105.	2.0	12
294	Pseudomonas aeruginosa Resistance to Bacteriophages and Its Prevention by Strategic Therapeutic Cocktail Formulation. Antibiotics, 2021, 10, 145.	1.5	14
295	From genotype to phenotype: adaptations of Pseudomonas aeruginosa to the cystic fibrosis environment. Microbial Genomics, 2021, 7, .	1.0	23
296	Trehalose and Î±-glucan mediate distinct abiotic stress responses in Pseudomonas aeruginosa. PLoS Genetics, 2021, 17, e1009524.	1.5	22
297	Compensatory evolution of Pseudomonas aeruginosaâ€™s slow growth phenotype suggests mechanisms of adaptation in cystic fibrosis. Nature Communications, 2021, 12, 3186.	5.8	33
298	The antiâ€sigma factor MucA is required for viability in Pseudomonas aeruginosa. Molecular Microbiology, 2021, 116, 550-563.	1.2	11
299	Semiparametric estimation of the proportional rates model for recurrent events data with missing event category. Statistical Methods in Medical Research, 2021, 30, 1624-1639.	0.7	2

#	Article	IF	Citations
300	Ecoâ€physiological portrait of a novel Pseudomonas sp. CSV86 : An ideal host/candidate for metabolic engineering and bioremediation. Environmental Microbiology, 2021, , .	1.8	12
301	The role of Psl in the failure to eradicate Pseudomonas aeruginosa biofilms in children with cystic fibrosis. Npj Biofilms and Microbiomes, 2021, 7, 63.	2.9	18
302	Genomic Features of Pseudomonas putida Strain KT2440. , 2004, , 77-112.		11
303	Emergence of Pseudomonas aeruginosa in Cystic Fibrosis Lung Infections. , 2010, , 141-175.		2
306	Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats. Infection and Immunity, 1994, 62, 1427-1436.	1.0	76
307	Pseudomonas aeruginosa from Patients with Cystic Fibrosis Affects Function of Pulmonary Surfactant. Pediatric Research, 2000, 47, 121-121.	1.1	24
308	Exome Sequencing of Phenotypic Extremes Identifies CAV2 and TMC6 as Interacting Modifiers of Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis. PLoS Genetics, 2015, 11, e1005273.	1.5	39
309	Neutrophil Extracellular Trap (NET)-Mediated Killing of Pseudomonas aeruginosa: Evidence of Acquired Resistance within the CF Airway, Independent of CFTR. PLoS ONE, 2011, 6, e23637.	1.1	194
310	Phenotypic Heterogeneity of Pseudomonas aeruginosa Populations in a Cystic Fibrosis Patient. PLoS ONE, 2013, 8, e60225.	1.1	177
311	Dielectrophoresis-Based Discrimination of Bacteria at the Strain Level Based on Their Surface Properties. PLoS ONE, 2013, 8, e76751.	1.1	47
312	A High Level of Soluble CD40L Is Associated with P. aeruginosa Infection in Patients with Cystic Fibrosis. PLoS ONE, 2016, 11, e0168819.	1.1	3
313	A multifunctional bispecific antibody against Pseudomonas aeruginosa as a potential therapeutic strategy. Annals of Translational Medicine, 2016, 4, 12.	0.7	4
314	Infektionen der unteren Atemwege. , 2004, , 243-300.		0
315	Cystic fibrosis infection with clonal strains of Pseudomonas aeruginosa: current knowledge and future management. , 2006, , 105-126.		1
316	Pseudomonas Aeruginosa in Cystic Fibrosis Patients with CFTR 11234V in a Large Kindred Family. Qatar Medical Journal, 2010, 2010, .	0.2	0
317	Introduction to Section I: The Relevance of CF Diagnostic Tools for Measuring Restoration of CFTR Function After Therapeutic Interventions in Human Clinical Trials. Methods in Molecular Biology, 2011, 741, 3-11.	0.4	1
319	Obstructive Pulmonary Diseases. , 1999, , 185-225.		0
320	Analysis of Cystic Fibrosis in Federation of Bosnia and Herzegovina. Medicinski Arhiv = Medical Archives = Archives De MÃ©decine, 2015, 69, 222.	0.4	0

#	Article	IF	Citations
321	Anti-Infective Therapies in Cystic Fibrosis. Milestones in Drug Therapy, 2017, , 153-169.	0.1	0
322	Clinical Application of Stem/Stromal Cells in Cystic Fibrosis. , 2019, , 179-198.		0
323	Viruses and the lung microbiome. , 2019, , 119-139.		1
325	Bacterial Infections and the Respiratory Microbiome. Respiratory Medicine, 2020, , 73-92.	0.1	2
327	The determinants of survival among adults with cystic fibrosisâ€"a cohort study. Journal of Physiological Anthropology, 2021, 40, 19.	1.0	20
330	Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex. Journal of the Royal Society of Medicine, 2000, 93 Suppl 38, 40-5.	1.1	11
331	A role for CD4+ T cells from orally immunized rats in enhanced clearance of Pseudomonas aeruginosa from the lung. Immunology, 1994, 83, 362-9.	2.0	57
332	Functional genome mining and taxonoâ€genomics reveal ecoâ€physiological traits and species distinctiveness of aromaticâ€degrading Pseudomonas bharatica sp. nov.. Environmental Microbiology Reports, 2022, , .	1.0	6
335	Crosstalk between Body Microbiota and the Regulation of Immunity. Journal of Immunology Research, 2022, 2022, 1-13.	0.9	3
336	The potential of volatile organic compound analysis for pathogen detection and disease monitoring in patients with cystic fibrosis. Expert Review of Respiratory Medicine, 2022, 16, 723-735.	1.0	3
337	Adaptation and Evolution of Pathogens in the Cystic Fibrosis Lung. Journal of the Pediatric Infectious Diseases Society, 2022, 11, S23-S31.	0.6	11
338	Longitudinal Magnetic Resonance Imaging Detects Onset and Progression of Chronic Rhinosinusitis from Infancy to School Age in Cystic Fibrosis. Annals of the American Thoracic Society, 2023, 20, 687-697.	1.5	6
339	Polymicrobial Biofilms in Cystic Fibrosis Lung Infections: Effects on Antimicrobial Susceptibility. Springer Series on Biofilms, 2023, , 231-267.	0.0	2
340	The Burkholderia contaminans prevalent phenotypes as possible markers of poor clinical outcomes in chronic lung infection of children with cystic fibrosis. Pathogens and Disease, 2023, 81, .	0.8	0